ADTRAN
28.5.2024 14:01:26 CEST | Business Wire | Press release
Adtran today announced that the Swedish University Computer Network (SUNET) has deployed its ALM in-service fiber monitoring solution to enhance network resilience and operational efficiency. The technology equips SUNET’s maintenance teams with real-time insight into the quality of its nationwide backbone infrastructure and identifies the precise location of any fiber issues. As Sweden’s research and education (R&E) network, SUNET empowers academics and scientists across the country to access learning resources, conduct research and collaborate internationally. With the deployment of ALM, the Nordics’ R&E community has additional assurance of uninterrupted, high-quality services. NetNordic, a key technology partner of SUNET, was also involved in the deployment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528454910/en/
Adtran’s ALM is helping SUNET monitor its national fiber network to rapidly identify faults and support swift resolution. (Photo: Business Wire)
“SUNET is a world-class high-capacity optical transport network connecting over 110 organizations and serving a community of 750,000 students, teachers and researchers across Sweden and beyond. The deployment of our ALM platform, with its passive fiber monitoring capabilities, has built even more resilience into this crucially important infrastructure, rendering services more reliable and streamlining operations,” said Stuart Broome, GM of EMEA sales at Adtran. “Finding the exact location of faults is a huge challenge for any operator. But now, with the ability to monitor the integrity of its fiber plant passively and proactively, SUNET’s maintenance teams no longer have to engage in costly and complicated post-failure analysis. ALM enables them to address issues before they impact the high-bandwidth, low-latency services Sweden’s R&E community relies on.”
The deployment of Adtran’s 16-port ALM fiber assurance solution across SUNET’s extensive fiber 8,000km backbone network enables rapid identification and resolution of failures, enhancing network resilience. This is a crucial advantage for a user community involved in data-heavy scientific research. The technology also helps improve efficiency by enabling proactive maintenance. Through an intuitive graphical user interface, SUNET can leverage ALM to monitor a vast national infrastructure containing RAMAN-amplified optical links. The platform detects abnormal attenuation, fiber breaks, tapping attempts and other issues that have the potential to impact connection quality and service availability. ALM also boosts sustainability by cutting down on truck rolls, while its low power use and fanless design ensure a greener, less resource-heavy network.
“From climate science to engineering to medicine, SUNET supports a wide range of important data-intensive projects. That’s why its infrastructure needs to be both fast and highly reliable. Our ALM technology guarantees peak network efficiency and resilience against unpredictable challenges like excavation damage or severe storms. With 24/7 monitoring capabilities, it enables SUNET’s maintenance teams to quickly identify and rectify any issues, ensuring uninterrupted, high-quality service,” commented Sander Jansen, GM of infrastructure monitoring at Adtran. “Moreover, our technology enhances environmental sustainability by reducing unnecessary site visits and lowering carbon footprint. This creates a network that benefits not just today’s users but also future generations.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About SUNET
SUNET, the Swedish University Computer Network, has served the Swedish universities and other organizations closely related to research and education for more than 40 years. We provide the connected organizations with access to well-developed and effective national and international data communication, a national academic identity infrastructure and other related services that meet their needs, regardless of their geographical location. We are part of the Swedish Research Council and connect Sweden through 8400 km of nationwide dark fiber. For more information, please visit www.sunet.se.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528454910/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom